According to Avalon Pharma (Middle East Pharmaceutical)'s latest financial reports the company's current EPS (TTM) is ยฃ0.70. In 2024 the company made an earnings per share (EPS) of ยฃ0.80 an increase over its 2023 EPS that were of ยฃ0.66.